TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05134805

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bipolar hemiarthroplasty , proximal femoral nail
Description: * Removal of head of femur , greater trochanter , and lesser trochanter and use bioplar hemiarthroplasty (BHA).~* Intra-medullary fixation of intertrchanteric femoral fracture by proximal femoral nail (PFN) Fixation of the fracture by using intramedullary nail(proximal femoral nail).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bipolar hemiarthroplasty , proximal femoral nail
Description: * Removal of head of femur , greater trochanter , and lesser trochanter and use bioplar hemiarthroplasty (BHA).~* Intra-medullary fixation of intertrchanteric femoral fracture by proximal femoral nail (PFN) Fixation of the fracture by using intramedullary nail(proximal femoral nail).
Study: NCT04120896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Karate group
Description: Children in the karate group will receive the basic Goju Ryu Karate training that includes basic stances (dachi), punching (zuki), blocking (barai) and kicking techniques (keri), form training (kata), supervised sparring (kumite), and conditioning exercises (for warm up and cool down).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kung fu group
Description: Children in the Ving Tsun kung fu group will receive the basic Wong Shun Leung style Ving Tsun training that includes basic stances (ma), footwork (bu), punching (quan), kicking (jie) techniques and conditioning exercises (for warm up and cool down).
Study: NCT00009737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 425mg/m2 iv daily from day 1 to day 5 every 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 20mg/m2 iv daily from day 1 to day 5 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine [Xeloda]
Description: 1250mg/m2 po bid on days 1-14 every 21 days.
Study: NCT01785043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin is available in 100 mg film-coated tablets (Januvia®). Each tablet contains sitagliptin phosphate monohydrate, equivalent to 100 mg sitagliptin.
Study: NCT01176578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: 6 months of aerobic exercise training, 3 days per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: 6 months of aerobic exercise training, 3 days per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: 6 months of aerobic exercise training, 3 days per week
Study: NCT03049371

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention for both groups
Description: No Intervention for both groups However, computer-administered questionnaire will collect quantitative demographic information and details about surgical history, neovaginal health, neovaginal practices, and sexual behavior including neovaginal intercourse and drug use history from each participant
Study: NCT03539848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-PAS Goggles
Description: Portable, head-mounted display goggle system with integrated eye capture technology

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-PAS Goggles
Description: Portable, head-mounted display goggle system with integrated eye capture technology
Study: NCT01093716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Rapid® (rTMS)
Description: Ten daily sessions of rTMS treatments using Magstim Rapid® device (10 Hz, 110% of the MT, 4.9 seconds per train, inter-train interval of 30 seconds, and 20 trains per session) with an air cooled figure-of-eight coil over either right or left DLPFC
Study: NCT01696227

Intervention type: DRUG
Intervention: Nissle 1917
Description: Uropathogens will be challenged to share the same in vitro environment with Nissle 1917.
Study: NCT02192541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept
Description: Ziv-aflibercept is a soluble fusion protein with high binding affinity for vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), and placenta growth factor (PIGF) and thus confers anti-angiogenic activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Ganetespib is a non-geldamycin synthetic inhibitor of Hsp90 with activity against multiple cancer cell lines and tumor xenografts in preclinical models.
Study: NCT04193033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLOW intervention
Description: The FLOW program, including internal and external facilitation, use of the FLOW online report to identify patients, patient and provider education materials, a medical record template, and regular data tracking and feedback about the process.
Study: NCT03023007

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loco-regional anaesthesia
Description: Loco-regional anaesthesia
Study: NCT03371680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 1-13 Carbon Leucine and deuterated water
Description: All patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
Study: NCT01695837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6
Study: NCT01480882

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Chest Physiotherapy (CCPT)
Description: Conventional chest percussion will be applied for a duration of 15 minutes.
Study: NCT01807585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenaSeal SCS
Description: Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClosureFast Radiofrequency Ablation (RFA)
Description: Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
Study: NCT01874717

Intervention type: DRUG
Group type: OTHER
Intervention: midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Study: NCT00244751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI262570 0.5 mg
Description: GI262570 0.5 mg
Study: NCT01901640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8159 (Udenafil)
Study: NCT05643014

Intervention type: OTHER
Intervention: Sample collection
Description: This study will involve three sample collections including buccal cells and urine samples
Study: NCT04259164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVM149
Description: Anti-inflammatory effect of Glycopyrronium added to Mometasone / Indacaterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QMF149
Description: Mometasone / Indacaterol
Study: NCT01480882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical percussion (LEGA)
Description: Mechanical chest percussion will be delivered by a device for 15 minutes.
Study: NCT02681861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6294 Intravenous
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6294 Subcutaneous
Description: Subcutaneous (SC)
Study: NCT00128518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indapamide (T2)
Description: 1.5 mg/day during 4 weeks
Study: NCT02681861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Intravenous
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Subcutaneous
Description: Subcutaneous (SC)
Study: NCT03982511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCIT-Health
Description: PCIT-Health (also known as Parents Active in Their Children's Health; PATCH) is an adaptation of Parent-Child Interaction Therapy. PCIT-Health targets (1) the parent-child relationship and (2) parenting efficacy both in general contexts (child play time and clean up time) and specifically in the context of obesity risk-related behaviors (child feeding, family mealtime, and child screen time).
Study: NCT01991743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2.5
Description: Administration of bupivacaine 2.5 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 5
Description: Administration of 5 mg bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 7.5
Description: Administration of 7.5 mg bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 10
Description: Administration of 10mg bupivacaine.
Study: NCT05479786

Intervention type: OTHER
Intervention: Expectant management
Description: Follow-up with beta-HCG dosages and transvaginal ultrasound scans

Intervention type: PROCEDURE
Intervention: Salpingectomy
Description: Removal of the affected Fallopian tube by laparoscopy

Intervention type: PROCEDURE
Intervention: Salpingostomy
Description: Removal of the ectopic pregnancy from the Fallopian tube, without removing the whole Fallopian tube, by laparoscopy
Study: NCT03692286

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Silver nanoparticle/Calcium hydroxide
Description: Intracanal Medication composed of combined silver nanoparticles with calcium hydroxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nanoparticles in gel form
Description: Intracanal medication composed of silver nanoparticles in gel form
Study: NCT01807585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roll-in (VenaSeal SCS)
Description: Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
Study: NCT03272100

Intervention type: PROCEDURE
Intervention: flap
Description: after flap incision , the sinus cavity was opened and then the membrane raised up

Intervention type: PROCEDURE
Intervention: flap
Description: after flap incision , the sinus cavity was opened and then the membrane raised up
Study: NCT01394861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESD using Master Slave Robotic System
Description: Endoscopic submucosal dissection of early gastric cancer or broad sessile polyp using Master Slave Robotic System
Study: NCT00244751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI262570 1.0 mg
Description: GI262570 1.0 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03651271

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab Monotherapy
Description: Single-agent nivolumab will be administered at 360 mg IV Q3W. Participants who continue to show clinical benefit after the first disease assessment will receive nivolumab 480 mg IV Q4W until PD or intolerable toxicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab Monotherapy
Description: Single-agent nivolumab will be administered at 360 mg IV Q3W. Participants who continue to show clinical benefit after the first disease assessment will receive nivolumab 480 mg IV Q4W until PD or intolerable toxicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab and Combination for Metastatic Cancer
Description: For nivolumab and ipilimumab combination therapy, nivolumab will be administered at 360 mg IV Q3W, and ipilimumab will be administered at 1 mg/kg IV Q3W for the first 2 doses and then Q6W for the 3rd and 4th doses, followed by single-agent nivolumab 480 mg IV Q4W until PD or intolerable toxicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer
Description: For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort A will receive nivolumab 1 mg/kg Q3W and ipilimumab 3 mg/kg every 6 weeks (Q6W) for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If the safety profile of Prostate Cohort B is deemed unacceptable, an additional 10 participants will be enrolled in Prostate Cohort A.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer
Description: For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort B will receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If Prostate Cohort B is determined to have a tolerable safety profile, an additional 10 participants will be enrolled to receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity.
Study: NCT00128518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indapamide (T2)
Description: 1.5 mg/day during 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indapamide (T2)
Description: 1.5 mg/day during 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indapamide (T2)
Description: 1.5 mg/day during 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril (T1)
Description: 4 mg/day during 1 week then 8 mg/day during 3 weeks
Study: NCT04704245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidermal growth factor (EGF)-containing ointment
Description: The subjects applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Description: To compare the effect of epidermal growth factor (EGF) ointment, the control subjects applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser
Description: The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser
Description: The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening.
Study: NCT01902017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen
Description: 5 mg PO bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen
Description: 5 mg PO bid
Study: NCT00128518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril (T1)
Description: 4 mg/day during 1 week then 8 mg/day during 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril (T1)
Description: 4 mg/day during 1 week then 8 mg/day during 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril (T1)
Description: 4 mg/day during 1 week then 8 mg/day during 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Perindopril (P1)
Description: 1 pill/day during 1 week then 2 pills/day during 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Perindopril (P1)
Description: 1 pill/day during 1 week then 2 pills/day during 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Perindopril (P1)
Description: 1 pill/day during 1 week then 2 pills/day during 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Perindopril (P1)
Description: 1 pill/day during 1 week then 2 pills/day during 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Indapamide (P2)
Description: 1 pill/day during 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Indapamide (P2)
Description: 1 pill/day during 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Indapamide (P2)
Description: 1 pill/day during 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Indapamide (P2)
Description: 1 pill/day during 4 weeks
Study: NCT03778190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal Foreign Body Removal
Description: An eye magnet will be brought close to the foreign body on the surface of the eye in an attempt to remove the foreign body.
Study: NCT01467401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart
Description: Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin
Description: Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
Study: NCT01247753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking group
Description: Internet-mediated pedometer-based walking program with gradually increasing step count goals and feedback on step counts. Also includes nutritional coaching course consisting of 1 individual session with a dietician, 4 group sessions, and monthly follow-up. Oral glucose tolerance tests pre and post-intervention.
Study: NCT03852407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: ATG: 2.5 mg /kg/day on day -2 and -1 (day 0 is allogenic transplantation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100mg/m² on day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100mg/m² on day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m² on days -6, -5, -4, -3, and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m² on days -6, -5, -4, -3, and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: 50 mg/kg on days +3 and +4.
Study: NCT03567200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-Arm Feasibility
Description: Participants in each of the 8 participating groups (N=10-12 per group) are exposed to an integrated intervention program (integration of physical activity and psychosocial components). Each session is co-facilitated by a trained research staff member and a registered social worker, providing participants with the opportunity to engage in physical activity behaviours as well as discuss various psychosocial topics that are applicable to the participants interests. Physical activities include participating in group activities such as rock climbing, self-defence, yoga, etc. Psychosocial topics addressed include group discussions around cyber-bullying, sexual abuse and exploitation, gender issues, etc.
Study: NCT02260752

Intervention type: PROCEDURE
Intervention: hysterectomy
Description: surgical removal of the uterus

Intervention type: PROCEDURE
Intervention: Uterine arterial embolization
Description: In uterine artery embolization, doctor uses a slender, flexible tube (catheter) to inject small particles (embolic agents) into the uterine arteries, which supply blood to your fibroids and uterus.the embolic agents are injected into these fibroid blood vessels. The goal is to block the fibroid vessels, starving the fibroids and causing them to shrink and die.

Intervention type: PROCEDURE
Intervention: myomectomy
Description: surgical procedure to remove uterine fibroids, but does not remove uterus

Intervention type: DRUG
Intervention: Medical Therapy
Description: treatment of uterine fibroids with only medications, no procedure or surgery is used

Intervention type: PROCEDURE
Intervention: endometrial ablation
Description: surgical procedure that destroys uterine lining via a telescope placed inside the uterus

Intervention type: PROCEDURE
Intervention: magnetic resonance guided focused ultrasound
Description: procedure that destroys fibroids while inside an MRI machine

Intervention type: PROCEDURE
Intervention: radiofrequency ablation
Description: procedure that uses heat to destroy uterine fibroids
Study: NCT03797339

Intervention type: OTHER
Intervention: risk factors of adverse cardiovascular events
Description: During the follow-up period,general information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters will be collected

Intervention type: OTHER
Intervention: risk factors of adverse cardiovascular events
Description: During the follow-up period,general information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters will be collected

Intervention type: OTHER
Intervention: multi-omics target discovery
Description: Genome-wide genotype , DNA methylation and metabolomes were determined using illumina high-density genotyping chips, high-throughput sequencing, and high-resolution mass spectrometry respectly. Blood exposure of statins and metoprolol and its metabolites was determined by UPLC-MS/MS.

Intervention type: OTHER
Intervention: validation
Description: The genome-wide genotype of patients with coronary heart disease was detected using the illumina chip. The methylation level of the functional region was detected by the target region enrichment methylation sequencing method. Intestinal flora differences were detected using 16SrDNA high-throughput sequencing.

Intervention type: OTHER
Intervention: Predictive mathematical models
Description: Machine learning algorithms such as multiple linear regression or Bayesian classification are used to optimize clinical factors and multi-group targets to establish predictive mathematical models.
Study: NCT02404779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium besilate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo